Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Clarithromycin is a widely used semi-synthetic macrolide antibiotic derived from erythromycin, distinguished by the addition of a methoxy group at the C9 position. This structural modification significantly enhances its acid stability and extends its spectrum of activity against Gram-positive bacteria compared to its predecessor. The chemical identity of Clarithromycin is defined by the molecular formula C38H69NO13 and it is universally recognized by the CAS Registry Number 81103-11-9. Its systematic IUPAC name reflects its complex macrocyclic lactone structure, which includes a desosamine and cladinose sugar moiety essential for its biological function.
The primary clinical application of Clarithromycin involves the treatment of various bacterial infections affecting the respiratory tract, skin, and soft tissues. It is highly effective against pathogens such as Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis, making it a first-line therapy for community-acquired pneumonia, acute exacerbations of chronic bronchitis, and sinusitis. Furthermore, it plays a critical role in the management of Mycobacterium avium complex (MAC) infections, particularly in patients with HIV/AIDS, often used in combination with other antitubercular agents. In gastrointestinal medicine, Clarithromycin is a key component of triple or quadruple therapy regimens designed to eradicate Helicobacter pylori, thereby reducing the risk of peptic ulcers and gastric cancer.
Mechanistically, Clarithromycin exerts its bacteriostatic or bactericidal effects by binding reversibly to the 50S subunit of the bacterial ribosome. This interaction inhibits protein synthesis by blocking the translocation step during peptide chain elongation, effectively halting bacterial growth and replication. While generally well-tolerated, common side effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal pain, as well as taste perversion. Clinicians must exercise caution regarding drug-drug interactions, as Clarithromycin is a potent inhibitor of cytochrome P450 3A4, potentially altering the metabolism of concomitant medications like statins or warfarin. Despite these considerations, its robust efficacy profile ensures its continued status as a vital therapeutic agent in modern antimicrobial pharmacotherapy.